Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 35OTHER_GOV 6INDUSTRY 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Stomach Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasms 1Keratosis, Actinic 1Heart Failure 1Gastrointestinal Neoplasms 1Disease 1Colorectal Neoplasms 1Breast Neoplasms 1Biliary Tract Neoplasms 1Arrhythmias, Cardiac 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × Control Groups × Clear all
NCT06039644 2026-03-06

To Evaluate the Clinical Efficacy of Probiotics in Patients With the Breast Cancer

GenMont Biotech Incorporation

Phase NA Recruiting
100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡